Results 1 to 10 of about 21,197 (211)

Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo

open access: yesActa Pharmaceutica Sinica B, 2021
Multidrug resistance (MDR) mediated by ATP binding cassette subfamily B member 1 (ABCB1) is significantly hindering effective cancer chemotherapy. However, currently, no ABCB1-inhibitory drugs have been approved to treat MDR cancer clinically, mainly due
, Jing Guo, Thomas Efferth
exaly   +3 more sources

Cloning, structural and functional characterization of the ABCB1 transporter of the Eurasian bullfinch (Pyrrhula pyrrhula) [PDF]

open access: yesFrontiers in Veterinary Science
Suspected ivermectin hypersensitivity has been reported in the Eurasian bullfinch and some related passerine birds. However, the underlying cause and pharmacological mechanism have not been systematically investigated.
Katharina Heilmann   +5 more
doaj   +2 more sources

ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma

open access: yesCells, 2020
The ATP Binding Cassette transporter B1 (ABCB1) induces chemoresistance in osteosarcoma, because it effluxes doxorubicin, reducing the intracellular accumulation, toxicity, and immunogenic cell death induced by the drug.
Massimo Donadelli   +2 more
exaly   +3 more sources

H89 Reverses Multidrug Resistance in Colorectal Cancer by Inhibiting the ATPase Activity of ABCB1 [PDF]

open access: yesBiomedicines
Background: Multidrug resistance (MDR) remains a major obstacle in cancer chemotherapy, and overexpression of ABCB1 plays a critical role in the pathogenesis of MDR.
Wei-Jing Liu   +9 more
doaj   +2 more sources

Lack of Association between C1236T, G2677T/A and C3435T Variants of the ABCB1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients [PDF]

open access: yesJournal of Sciences, Islamic Republic of Iran, 2021
Imatinib introduction caused to improve the clinical outcomes of chronic myeloid leukemia (CML) patients. Despite the significant effects of Imatinib, pharmacogenetic variables induced treatment resistant is also observed.
Maedeh Khosravi   +7 more
doaj   +1 more source

Minimally invasive differential diagnosis of melanocytic intraocular neoplasms

open access: yesРоссийский офтальмологический журнал, 2023
Purpose: to analyze the mutation frequency of the GNAQ/GNA11 gene in circulating tumor DNA and genotypes of the polymorphic marker C3435T of the ABCB1 gene in a large sample of patients with intraocular melanocytic neoplasms (IMN).Material and methods ...
A. Yu. Tsygankov   +4 more
doaj   +1 more source

The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients

open access: yesRadiology and Oncology, 2023
Deregulation of the apoptotic process underlies the pathogenesis of many cancers, including leukemia, but is also very important for the success of chemotherapy treatment.
Pravdic Zlatko   +6 more
doaj   +1 more source

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

open access: yesOpen Life Sciences, 2021
Clopidogrel is an antiplatelet drug that displays significant interindividual variability in treatment response. Its bioavailability depends on the function of P-glycoprotein (P-gp), which is coded by a highly polymorphic ABCB1 gene.
Mugosa Snezana   +4 more
doaj   +1 more source

PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study

open access: yesMolecular Cancer, 2022
Highlights ABCB1 overexpression significantly desensitized both drug-selected and gene-transfected cells, which overexpress ABCB1, to OTS964 and that this drug resistance can be antagonized by verapamil, a known ABCB1 inhibitor.
Yuqi Yang   +8 more
doaj   +1 more source

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

open access: yesFrontiers in Pharmacology, 2022
Palbociclib was approved by the United States Food and Drug Administration for use, in combination with letrozole, as a first-line treatment for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) postmenopausal ...
Han Fu   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy